Blueprint Neurotherapeutics Network (BPN)
Department of Health and Human Services
Funding amounts are not limited but must reflect actual project needs.
UG3 phase funding can last up to 2 years; UH3 phase can last up to 4 years.
To accelerate the development of diverse biotherapeutic modalities for nervous and neuromuscular disorders.
NIH Institutes and Centers, researchers, and patients with nervous system disorders.
National Institutes of Health (NIH)
Cooperative Agreement
Recurring grant opportunity with multiple application deadlines.
Higher Education Institutions
Public/State Controlled Institutions
Private Institutions
Nonprofits
For-Profit Organizations
Small Businesses
Local, State, County, and City Governments
Indian/Native American Tribal Governments
Federal Government Agencies
Foreign Organizations
Must have an eRA Commons account for PD/PI.
Registration in System for Award Management (SAM) is required.
Organizations from the US and foreign entities are eligible.
Not specified
Biologics-based therapies for nervous and neuromuscular disorders.
Lead optimization and first-in-human clinical trials.
Expertise in biologics development, including regulatory and industry experience.
Compliance with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP).
Application budgets are not limited but must reflect actual needs.
No cost sharing is required.
Open Date: December 27, 2024
Application Due Dates: Various dates from January 2025 to August 2027.
Compliance with NIH policies and federal regulations.
Gantt Chart, IP Strategy, and other application forms as specified.